SCHEDULE: Wellington Management Discloses Stake in Stoke Therapeutics

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 5.2% of Stoke Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, has filed a Schedule 13G.
• This filing indicates beneficial ownership of 3,095,700 shares of Stoke Therapeutics, Inc. common stock.
• This represents approximately 5.2% of the class of securities.
• The filing is dated March 31, 2026, and was signed on May 15, 2026.
• The reporting entities are classified as investment advisers (IA) and holding companies (HC).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports an existing ownership stake rather than new developments or financial performance.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by Wellington Management indicates a significant institutional investor's stake in Stoke Therapeutics, a biotechnology company. Such filings often signal confidence or a strategic interest from large asset managers.

Stakeholder Impact

• Shareholders: The filing confirms a substantial institutional holding by Wellington Management, which may be viewed positively by the market as an endorsement of the company's prospects.
• Company Management: The presence of a significant institutional investor can influence corporate strategy and governance discussions.

Key Dates

Keywords

Stoke Therapeutics, Wellington Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, SEC Filing